Schroder Investment Management Group Increases Position in Stryker Co. (NYSE:SYK)

Schroder Investment Management Group boosted its position in Stryker Co. (NYSE:SYKFree Report) by 8.3% in the 4th quarter, Holdings Channel reports. The fund owned 701,339 shares of the medical technology company’s stock after purchasing an additional 53,910 shares during the period. Schroder Investment Management Group’s holdings in Stryker were worth $210,023,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Burkett Financial Services LLC purchased a new position in shares of Stryker during the 4th quarter worth about $25,000. Farmers & Merchants Trust Co of Chambersburg PA increased its position in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares during the last quarter. Rogco LP acquired a new position in shares of Stryker in the 4th quarter valued at $30,000. DSM Capital Partners LLC acquired a new position in Stryker in the fourth quarter valued at $34,000. Finally, HBC Financial Services PLLC acquired a new stake in Stryker during the fourth quarter worth about $37,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Down 0.1 %

Shares of Stryker stock traded down $0.30 during trading on Friday, reaching $349.33. The company had a trading volume of 847,236 shares, compared to its average volume of 1,371,109. The company has a market cap of $133.08 billion, a price-to-earnings ratio of 39.88, a price-to-earnings-growth ratio of 2.75 and a beta of 0.92. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm’s fifty day moving average is $337.38 and its 200-day moving average is $328.08. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71.

Stryker (NYSE:SYKGet Free Report) last released its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The company had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter last year, the business posted $2.14 EPS. Stryker’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts anticipate that Stryker Co. will post 11.95 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.92%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Royal Bank of Canada boosted their target price on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Robert W. Baird raised their target price on shares of Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Evercore ISI lifted their target price on shares of Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays increased their price target on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Finally, TD Cowen boosted their price objective on Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $370.58.

View Our Latest Stock Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Read More

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.